Funding of the EORTC

The EORTC is funded through several sources including the EORTC Charitable Trust providing a core grant which is mainly supported by numerous national cancer leagues.

Since 1972, the US National Cancer Institute (NCI) has provided core support to EORTC Headquarters, and with this support a close scientific collaboration has been maintained to promote transatlantic research projects.

A core grant from the Fonds Cancer, FOCA (BE), provides support for the EORTC Headquarters staff.

EORTC Headquarters receives annual grants allocated by BELSPO (the Belgian Federal Science Policy Office) and by the Belgian National Lottery.

Funding for the Fellowship Program is provided by the EORTC Charitable Trust, Fonds Cancer, FOCA (BE), the Koningin Wilhelmina Fund, KWF (NL), and several leagues including La Ligue Nationale
contre le Cancer (FR) and the Vlaamse Liga tegen Kanker, VLK (BE).

In addition, grants for EORTC research projects are received from the European Commission under the 6th and the 7th Framework Programme and the Innovative Medicines Initiative (IMI).

The EORTC has received support for bio-banking in a prostate cancer clinical trial from the Institute for the encouragement of Scientific Research and Innovation of Brussels, ISRIB.

Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners. Pharmaceutical industry sponsorship is also provided in the form of “unrestricted grants” for EORTC conferences.

The finances of the EORTC include all accounts from the EORTC Headquarters as well as all EORTC Groups and Task Forces. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.


The Academic Research Fund

The EORTC Board initiated an Academic Research Fund to support academic clinical trials or research projects submitted to the Board. Selected trials are academic in nature with inadequate or no funding from other sources. A final decision at the Board level is required based on the strategic/added value the proposed clinical trial brings to the overall EORTC strategy.

Last updated 02-03-2011